Adverum Biotechnologies is a technology company.
Adverum Biotechnologies has raised $55.0M across 1 funding round.
Adverum Biotechnologies has raised $55.0M in total across 1 funding round.
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage gene therapy company focused on developing durable, single-administration treatments for highly prevalent ocular diseases like wet age-related macular degeneration (wet AMD), the leading cause of blindness globally.[1][2][3] It builds ixoberogene soroparvovec (Ixo-vec), an intravitreal (IVT) gene therapy that transforms retinal cells into biofactories producing aflibercept, an anti-VEGF protein, to replace frequent, painful eye injections every 4-8 weeks.[1][2] Adverum serves patients with debilitating retinal conditions, retinal specialists, and caregivers, solving the problem of treatment non-compliance and vision loss due to burdensome regimens that fail in real-world use.[2][3] With 139 employees in Redwood City, California, the company has shown clinical momentum through Phase 2 trials like LUNA for wet AMD, though it faced setbacks like trial-related vision issues in 2019.[1][3]
Founded in 2012 as Avalanche Biotechnologies, Adverum pivoted in May 2016 after acquiring Annapurna Therapeutics, adopting its current name and NASDAQ ticker (ADVM).[3] This merger expanded its focus to ocular and rare diseases, with Amber Salzman (former Annapurna CEO) briefly leading as CEO before departing in 2018.[3] Leadership churn continued: Athena Countouriotis resigned as CMO, Leone Patterson became CEO in 2018, and Laurent Fischer took over in 2020.[3] Pivotal moments include 2019 Phase 1 data revealing vision deterioration and inflammation (causing a 50% stock drop), FDA Orphan Drug Designation for ADVM-062 in blue-cone monochromacy (2022), and dosing the first LUNA Phase 2 patient for wet AMD (September 2022).[3] By December 2025, Eli Lilly and Company acquired Adverum, marking a major milestone.[3]
Adverum stands out in gene therapy through its proprietary next-generation AAV vector platform optimized for IVT delivery in physicians' offices.[1][2]
Adverum rides the gene therapy wave in ophthalmology, fueled by aging populations driving wet AMD prevalence and limitations of anti-VEGF injections (e.g., frequent dosing, compliance issues).[2][3] Timing aligns with maturing AAV vectors for ocular delivery, shifting from invasive sub-retinal methods to office-based IVT, broadening access.[1][2] Market forces like rising blindness rates and demand for one-time cures favor it, amid a biotech ecosystem where big pharma (e.g., Eli Lilly's 2025 acquisition) validates and scales platforms.[3] Adverum influences by pioneering durable retinal therapies, potentially transforming standards for millions and accelerating IVT gene tech adoption.
Post-acquisition by Eli Lilly in December 2025, Adverum's pipeline—led by Ixo-vec—gains resources for faster Phase 3 advancement and commercialization, targeting wet AMD market dominance.[3] Trends like AAV optimization and combination therapies will shape progress, with Lilly's expertise amplifying global reach. Its influence evolves from indie innovator to integrated powerhouse, redefining ocular care and tying back to its mission: one-time treatments preserving sight for life.[2]
Adverum Biotechnologies has raised $55.0M in total across 1 funding round.
Adverum Biotechnologies's investors include Venrock.
Adverum Biotechnologies has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Series B in April 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2014 | $55.0M Series B | Venrock |